Q-omics provides the consensus-scored SPATA4 profile across patient tissues and cancer cell-line models. SPATA4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SPATA4 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, SPATA4 RNA expression shows 16,687 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KICH, and UVM as cancer lineages where SPATA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA4 survival associations across molecular data types. SPATA4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA4 RNA expression–survival associations across cancer types. High SPATA4 expression shows unfavorable associations in COAD and GBM, but favorable associations in BRCA, ACC, KIRP and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for SPATA4 RNA expression.
This table summarizes SPATA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA4 shows lower tumor expression in KICH, THCA, LUAD, LUSC, BLCA and UCEC. The KICH box plot shows higher SPATA4 RNA expression in normal versus tumor tissue (log2 FC = −1.579, t-test p < 0.001).
This table shows molecular features associated with SPATA4 in patient tissues and cancer cell lines. In patient samples, SPATA4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUAD.
